Design of meningococcal factor H binding protein mutant vaccines that do not bind human complement factor H

Infection and Immunity

Volumn 80, Issue 8, 2012, Pages 2667-2677

  Pajon, Rolando ^a   Beernink, Peter T ^a   Granoff, Dan M ^a  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; COMPLEMENT FACTOR H; EPITOPE; FACTOR H BINDING PROTEIN; MENINGOCOCCUS VACCINE; SERINE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; IMMUNOGENICITY; MENINGOCOCCOSIS; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; SEQUENCE ANALYSIS;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; ARGININE; BACTERIAL PROTEINS; COMPLEMENT FACTOR H; GENE EXPRESSION REGULATION, BACTERIAL; HUMANS; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; MICE; MODELS, MOLECULAR; MUTATION; NEISSERIA MENINGITIDIS; PROTEIN BINDING; PROTEIN CONFORMATION; SERINE; VACCINES, SYNTHETIC;

EID: 84864793516     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00103-12     Document Type: Article

References (61)

1. Arnold K, Bordoli L, Kopp J, Schwede T. 2006. The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics 22:195-201.
2. Beernink PT, Caugant DA, Welsch JA, Koeberling O, Granoff DM. 2009. Meningococcal factor H-binding protein variants expressed by ep-idemic capsular group A, W-135, and X strains from Africa. J. Infect. Dis. 199:1360 -1368.
3. Beernink PT, Granoff DM. 2008. Bactericidal antibody responses induced by meningococcal recombinant chimeric factor H-binding protein vaccines. Infect. Immun. 76:2568 -2575.
4. Beernink PT, Granoff DM. 2009. The modular architecture of meningococcal factor H-binding protein. Microbiology 155:2873-2883.
5. Beernink PT, Leipus A, Granoff DM. 2006. Rapid genetic grouping of factor H-binding protein (genome-derived neisserial antigen 1870), a promising group B meningococcal vaccine candidate. Clin. Vaccine Immunol. 13:758 -763.
6. Beernink PT, Lopasso C, Angiolillo A, Felici F, Granoff D. 2009. A region of the N-terminal domain of meningococcal factor H-binding protein that elicits bactericidal antibody across antigenic variant groups. Mol. Immunol. 46:1647-1653.
7. Beernink PT, et al. 2011. A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination. J. Immunol. 186:3606 -3614.
8. Beernink PT, et al. 2012. The effect of human fH on immunogenicity of meningococcal native outer membrane vesicle vaccines with overexpressed factor H binding protein. PLoS Pathog. 8(5):e1002688. doi: 10.1371/journal.ppat.1002688.
9. Beernink PT, Shaughnessy J, Ram S, Granoff DM. 2010. Impaired immunogenicity of a meningococcal factor H-binding protein vaccine engineered to eliminate factor H binding. Clin. Vaccine Immunol. 17: 1074-1078.
10. Beernink PT, et al. 2008. Fine antigenic specificity and cooperative bactericidal activity of monoclonal antibodies directed at the meningococcal vaccine candidate, factor H-binding protein. Infect. Immun. 76:4232- 4240.
11. Beernink PT, et al. 2007. Prevalence of factor H-binding protein variants and NadA among meningococcal group B isolates from the United States: implications for the development of a multicomponent group B vaccine. J. Infect. Dis. 195:1472-1479.
12. Benkert P, Tosatto SC, Schomburg D. 2008. QMEAN: a comprehensive scoring function for model quality assessment. Proteins 71:261-277.
13. Bordoli L, et al. 2009. Protein structure homology modeling using SWISS-MODEL workspace. Nat. Protoc. 4:1-13.
14. Borrow R, Andrews N, Goldblatt D, Miller E. 2001. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect. Immun. 69:1568- 1573.
15. Cantini F, et al. 2006. Solution structure of the immunodominant domain of protective antigen GNA1870 of Neisseria meningitidis. J. Biol. Chem. 281:7220 -7227.
16. Cendron L, Veggi D, Girardi E, Zanotti G. 2011. Structure of the uncomplexed Neisseria meningitidis factor H-binding protein fHbp (rLP2086). Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 67:531- 535.
17. Dunphy KY, Beernink PT, Brogioni B, Granoff DM. 2011. Effect of factor H-binding protein sequence variation on factor H binding and survival of Neisseria meningitidis in human blood. Infect. Immun. 79:353- 359.
18. Fearon DT, Austen KF. 1977. Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms. Proc. Natl. Acad. Sci. U. S. A. 74: 1683-1687.
19. Findlow J, et al. 2010. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin. Infect. Dis. 51:1127-1137.
20. Fischetti VA, Horstmann RD, Pancholi V. 1995. Location of the complement factor H binding site on streptococcal M6 protein. Infect. Immun. 63:149 -153.
21. Fletcher LD, et al. 2004. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect. Immun. 72:2088 -2100.
22. Giuntini S, Reason DC, Granoff DM. 2011. Complement-mediated bactericidal activity of anti-factorHbinding protein monoclonal antibodies against the meningococcus relies upon blocking factor H binding. Infect. Immun. 79:3751-3759.
23. Granoff DM. 2010. Review of meningococcal group B vaccines. Clin. Infect. Dis. 50(Suppl 2):S54 -S65.
24. Granoff DM, Welsch JA, Ram S. 2009. Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera. Infect. Immun. 77:764 -769.
25. Harris SL, et al. 2011. Preclinical evidence for the potential of a bivalent fHBP vaccine to prevent Neisseria meningitidis serogroup C disease. Hum. Vaccin. 7:68 -74.
26. Harrison LH, Trotter CL, Ramsay ME. 2009. Global epidemiology of meningococcal disease. Vaccine 27:B51-B63.
27. Hellwage J, et al. 2001. The complement regulator factor H binds to the surface protein OspE of Borrelia burgdorferi. J. Biol. Chem. 276:8427- 8435.
28. Horstmann RD, Sievertsen HJ, Knobloch J, Fischetti VA. 1988. Antiphagocytic activity of streptococcal M protein: selective binding of complement control protein factor H. Proc. Natl. Acad. Sci. U. S. A. 85:1657- 1661.
29. Huson DH, Bryant D. 2006. Application of phylogenetic networks in evolutionary studies. Mol. Biol. Evol. 23:254 -267.
30. Jarva H, et al. 2002. Streptococcus pneumoniae evades complement attack and opsonophagocytosis by expressing the pspC locus-encoded Hic protein that binds to short consensus repeats 8-11 of factor H. J. Immunol. 168:1886 -1894.
31. Jiang HQ, et al. 2010. Broad vaccine coverage predicted for a bivalent recombinant factorHbinding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine 28:6086-6093.
32. Krissinel E, Henrick K. 2007. Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 372:774 -797.
33. Lewis LA, et al. 2010. The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement. PLoS Pathog. 6:e1001027. doi:10.1371/ journal.ppat.1001027.
34. Lyskov S, Gray JJ. 2008. The RosettaDock server for local protein-protein docking. Nucleic Acids Res. 36:W233-W238.
35. Madico G, et al. 2007. Factor H binding and function in sialylated pathogenic neisseriae is influenced by gonococcal, but not meningococcal, porin. J. Immunol. 178:4489-4497.
36. Madico G, et al. 2006. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J. Immunol. 177:501-510.
37. Mascioni A, et al. 2009. Structural basis for the immunogenic properties of the meningococcal vaccine candidate LP2086. J. Biol. Chem. 284:8738- 8746.
38. Masignani V, et al. 2003. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J. Exp. Med. 197:789 -799.
39. Meri S, Jordens M, Jarva H. 2008. Microbial complement inhibitors as vaccines. Vaccine 26(Suppl 8):I113-I117.
40. Mothibeli KM, et al. 2011. Distribution of factor H binding protein beyond serogroup B: variation among five serogroups of invasive Neisseria meningitidis in South Africa. Vaccine 29:2187-2192.
41. Murphy E, et al. 2009. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J. Infect. Dis. 200:379 -389.
42. National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC. http://grants.nih.gov/grants/olaw/Guide-for-the-Care-and-Use-of -Laboratory-Animals.pdf.
43. Pajon R, Beernink PT, Harrison LH, Granoff DM. 2010. Frequency of factor H-binding protein modular groups and susceptibility to crossreactive bactericidal activity in invasive meningococcal isolates. Vaccine 28:2122-2129.
44. Pajon R, Fergus AM, Koeberling O, Caugant DA, Granoff DM. 2011. Meningococcal factorHbinding proteins in epidemic strains from Africa: implications for vaccine development. PLoS Negl. Trop. Dis. 5:e1302. doi: 10.1371/journal.pntd.0001302.
45. Pangburn MK, Schreiber RD, Muller-Eberhard HJ. 1977. Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution. J. Exp. Med. 146:257-270.
46. Pettersen EF, et al. 2004. UCSF Chimera-a visualization system for exploratory research and analysis. J. Comput. Chem. 25:1605-1612.
47. Scarselli M, et al. 2011. Rational design of a meningococcal antigen inducing broad protective immunity. Sci. Transl. Med. 3:91ra62. doi: 10.1126/scitranslmed.3002234.
48. Schneider MC, et al. 2006. Functional significance of factor H binding to Neisseria meningitidis. J. Immunol. 176:7566 -7575.
49. Schneider MC, Exley RM, Ram S, Sim RB, Tang CM. 2007. Interactions between Neisseria meningitidis and the complement system. Trends Microbiol. 15:233-240.
50. Schneider MC, et al. 2009. Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature 458:890-893.
51. Seib KL, et al. 2011. Characterization of diverse subvariants of the meningococcal factor H (fH) binding protein for their ability to bind fH, to mediate serum resistance, and to induce bactericidal antibodies. Infect. Immun. 79:970 -981.
52. Sim RB, Twose TM, Paterson DS, Sim E. 1981. The covalent-binding reaction of complement component C3. Biochem. J. 193:115-127.
53. Snape MD, et al. 2010. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr. Infect. Dis. J. 29:e71- e79.
54. Vu DM, Pajon R, Reason DC, Granoff DM. 2012. A broadly crossreactive monoclonal antibody against an epitope on the N-terminus of meningococcal fHbp. Sci. Rep. 2:341.
55. Vu DM, et al. 2012. Enhanced bacteremia in human factor H transgenic rats infected by Neisseria meningitidis. Infect. Immun. 80:643- 650.
56. Vu DM, Wong TT, Granoff DM. 2011. Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and neisserial heparin binding antigen. Vaccine 29: 1968 -1973.
57. Wang X, et al. 2011. Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Vaccine 29:4739-4744.
58. Weiler JM, Daha MR, Austen KF, Fearon DT. 1976. Control of the amplification convertase of complement by the plasma protein beta1H. Proc. Natl. Acad. Sci. U. S. A. 73:3268 -3272.
59. Welsch JA, Ram S. 2008. Factor H and neisserial pathogenesis. Vaccine 26(Suppl 8):I40 -I45.
60. Welsch JA, Ram S, Koeberling O, Granoff DM. 2008. Complementdependent synergistic bactericidal activity of antibodies against factor Hbinding protein, a sparsely distributed meningococcal vaccine antigen. J. Infect. Dis. 197:1053-1061.
61. Welsch JA, Rossi R, Comanducci M, Granoff DM. 2004. Protective activity of monoclonal antibodies to genome-derived neisserial antigen 1870, a Neisseria meningitidis candidate vaccine. J. Immunol. 172:5606- 5615.